ENTITY
Ascletis Pharma

Ascletis Pharma (1672 HK)

112
Analysis
Health Care • China
Ascletis Pharma is a fully integrated biotechnology company focused on the research, development, production, marketing, and sale of innovative pharmaceutical products. The company's marketed products include Ritonavir tablets, GANOVO®, and ASCLEVIR® for Hepatitis C, and it has a robust pipeline primarily in metabolic diseases, viral diseases, and oncology. Ascletis Pharma is headquartered in Hangzhou, China, and was founded in 2011.
more
bearish•Haidilao
•27 Aug 2018 06:05

Last Week in GER Research: Haidilao, Xiaomi, Ping An, 111, Qutoutiao, Nio and Tesla

Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a differentiated...

Logo
495 Views
Share
bearish•Ascletis Pharma
•15 Aug 2018 10:27

Ascletis Pharma: Invalidation of Gilead Patents Won't Help

China's State Intellectual Property Office (SIPO) last week invalidated Gilead Sciences (GILD US) 's patent claims on the base compound for...

Share
bearish•Tesla
•13 Aug 2018 04:27

Last Week in GER Research: Tesla, Pinduoduo, Beigene, Koolearn, Pintec, STX and China Tower

Below is a recap of the key research produced by the Global Equity Research team. This week we highlight some detailed math on a potential Tesla...

Logo
486 Views
Share
bullish•BeOne Medicines
•13 Aug 2018 03:52

BeiGene (6160 HK): On a Stronger Post-Listing Footing than Ascletis

Hong Kong investors have had their first taste of biotech stocks with the recent listings of Ascletis Pharma Inc (1672 HK) and BeiGene Ltd (6160...

Logo
604 Views
Share
bullish•Haidilao
•11 Aug 2018 13:47

ECM Coverage Weekly Update (11 August 2018)

Aequitas Research puts out a weekly update on the deals we have covered recently, along with updates for upcoming IPOs. It has been a fairly quiet...

Share
x